Biotec Pharmacon ASA (BIOTEC.OL)

BIOTEC.OL

About

Biotec Pharmacon ASA is a Norway-based company that develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology. The Company has a portfolio of patents covering marine gene products for the molecular biology sector, and products with potentials within... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.82
Market Cap (Mil.):	kr162.30
Shares Outstanding (Mil.):	39.39
Dividend:	--
Yield (%):	--

Financials

	BIOTEC.OL	Industry	Sector
P/E (TTM):	--	35.66	35.83
EPS (TTM):	-0.83	--	--
ROI:	-60.79	19.36	18.72
ROE:	-60.79	20.07	19.54

Latest News about BIOTEC.OL

» More BIOTEC.OL News

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Biotec Pharmacon ASA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
Biotec Pharmacon ASA (BIOTEC) - Financial Analysis Review Provider: GlobalData	$125.00 Buy
Wright Investors Service Comprehensive Report for Biotec Pharmacon ASA Provider: Wright Reports	$460.00 Buy
Biotec Pharmacon ASA (BIOTEC) - Financial Analysis Review Provider: GlobalData	$125.00 Buy
Biotec Pharmacon ASA (BIOTEC) - Medical Equipment - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.